Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

Executive Summary

US FDA approval of Sublocade, the company's once-monthly buprenorphine depot injection, may help Indivior defend its opioid addiction franchise from generics and the competing Alkermes product Vivitrol. But another new rival is expected soon – a once-monthly product from Braeburn.

Advertisement

Related Content

Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade
Braeburn Gets CRL For CAM2038 In Opioid Use Disorder, Yields Ground To Indivior
Indivior's Monthly Injectable Buprenorphine Wins Panel Backing; US FDA May Limit Dosage
Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel